Effect of durvalumab in patients with unresectable stage 3 non-small cell lung cancer post-chemoradiotherapy.

被引：0
|
作者：
Thurlapati, Aswani
Dhaliwal, Lovekirat Singh
Chennapragada, Sumasri
Gutta, Pranavteja
Song, Diana
Ralla, Deepika
Comeau, Jill
Shi, Runhua
Beedupalli, Kavitha
机构：
[1] LSU Hlth Sci Ctr, Dept Internal Med, Shreveport, LA USA
[2] LSU Hlth Shreveport, Shreveport, LA USA
[3] ULM, LSU Hlth Shreveport, Feist Weiller Canc Ctr, Sch Pharm, Shreveport, LA USA
[4] LSU Hlth Sci Ctr, Shreveport, LA USA
[5] Baylor Coll Med, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8550
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [2] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [3] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
    Tomasini, Pascale
    Greillier, Laurent
    Boyer, Arnaud
    Jeanson, Arnaud
    Barlesi, Fabrice
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
  • [4] Influence of durvalumab consolidation on pneumonitis after chemoradiotherapy for unresectable non-small cell lung cancer
    Murata, Saori
    Horinouchi, Hidehito
    Morishita, Momoko
    Kaku, Sawako
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Okuma, Kae
    Kusumoto, Masahiko
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1396 - S1396
  • [5] Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events
    Miura, Yu
    Mouri, Atsuto
    Kaira, Kyoichi
    Yamaguchi, Ou
    Shiono, Ayako
    Hashimoto, Kosuke
    Nishihara, Fuyumi
    Shinomiya, Shun
    Akagami, Tomoe
    Murayama, Yoshitake
    Abe, Takanori
    Noda, Shin-ei
    Kato, Shingo
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    THORACIC CANCER, 2020, 11 (05) : 1280 - 1287
  • [6] Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Vokes, EE
    Crawford, J
    Bogart, J
    Socinski, MA
    Clamon, G
    Green, MR
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5045S - 5050S
  • [7] Treatment Outcome and Safety of Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Kim, S.
    Kim, N.
    Chung, S.
    Choi, J.
    Hyun, I.
    Yeo, Y.
    Park, J.
    Jang, S.
    Kim, T.
    Sim, Y.
    Lee, C.
    Kim, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [8] Real-Life Study of Patients with Unresectable Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy Followed by Durvalumab
    Tuller, M.
    Buela, G.
    Ferreira, Y.
    Antivero, A.
    Lupinacci, L.
    Basbus, L.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S607 - S608
  • [9] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
    Oh, H. -J.
    Park, C. -K.
    Kim, Y. -C.
    Kim, Y. -H.
    Ahn, S. -J.
    Jeong, W. G.
    Lee, J. Y.
    Lee, J. C.
    Choi, C. M.
    Ji, W.
    Song, S. Y.
    Choi, J.
    Lee, S. Y.
    Kim, H.
    Lee, S. Y.
    Park, J.
    Yoon, S. H.
    Joo, J. H.
    Oh, I. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295
  • [10] Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
    Park, Cheol-Kyu
    Lee, Sung-Woo
    Cho, Hyun-Ju
    Oh, Hyung-Joo
    Kim, Young-Chul
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Cho, Jae-Ho
    Oh, In-Jae
    CANCERS, 2023, 15 (04)
12345